Farmadex (dexamethasone) eye drops 0.1% 10 ml. vial №1


Manufacturer: Ukraine

Treatment of steroid-sensitive non-infectious inflammatory and allergic conditions of the conjunctiva, cornea, and anterior segment of the eye, including postoperative inflammatory reactions.



Farmadex Storage
active substance: dexamethasone;

1 ml of solution contains: dexamethasone sodium phosphate in terms of 100% dry matter – 1 mg;

Excipients: boric acid, sodium tetraborate, disodium edetate, benzalkonium chloride, water for injections.

Farmadex Dosage form
Eye drops.

Basic physical and chemical properties: transparent colorless liquid.

Farmadex Pharmacotherapeutic group
Anti-inflammatory drugs used in ophthalmology. Corticosteroids, simple drugs. Dexamethasone. Code ATX S01B A01.

Pharmacological properties


Corticosteroids have an anti-inflammatory effect by inhibiting vascular adhesive molecules of endothelial cells, cyclooxygenase I or II and the release of cytokines. As a result, the formation of inflammatory mediators is reduced and the adhesion of leukocytes to the vascular endothelium is inhibited, which prevents them from penetrating into the inflamed tissues of the eye. Dexamethasone has a pronounced anti-inflammatory effect with reduced mineralocorticoid effects compared to some other steroids and is one of the most potent anti-inflammatory drugs.


The ophthalmic bioavailability of dexamethasone after topical application to the eye was studied in patients who underwent cataract surgery. The maximum level of dexamethasone in the intraocular fluid, which is approximately 30 ng / ml, was reached within 2 hours. Then there was a decrease in concentration with a half-life of 3 hours.

Dexamethasone is excreted by metabolism. Approximately 60% of the dose is excreted in the urine as 6-β-hydroxydexamethasone. Unchanged dexamethasone was not detected in urine. The half-life from blood plasma is relatively short – 3-4 hours. Dexamethasone is approximately 77-84% bound to serum albumin. Clearance ranges from 0.111 to 0.225 l / h / kg, volume of distribution ranges from 0.576 to 1.15 l / kg. The bioavailability of dexamethasone when administered orally is approximately 70%.

Treatment of steroid-sensitive non-infectious inflammatory and allergic conditions of the conjunctiva, cornea and anterior segment of the eye, including inflammatory reactions in the postoperative period.

Hypersensitivity to the active substance or to any of the components of the drug.

Acute untreated bacterial infections.

Cowpox and chickenpox and other viral infections of the cornea and conjunctiva.

Fungal diseases of the eye structures.

Mycobacterial eye infections. Keratitis caused by herpes simplex.

Interaction with other medicinal products and other forms of interaction
Interaction studies with other drugs have not been performed.

Concomitant use of topical steroids and nonsteroidal anti-inflammatory drugs (NSAIDs) for topical use increases the risk of complications of corneal wound healing.

CYP3A4 inhibitors (including ritonavir and cobicistat) may decrease dexamethasone clearance, leading to more severe side effects and suppression of adrenal cortex function / Cushing’s syndrome. This combination should be avoided if the benefit does not outweigh the increased risk of systemic corticosteroid side effects, in which case systemic corticosteroid side effects in patients should be monitored.

The use of eye drops that dilate the pupils (atropine and other anticholinergic substances) and may cause an increase in intraocular pressure, along with dexamethasone in eye drops may lead to an additional increase in intraocular pressure.

If several topical medicines are applied to the eye at the same time, the interval between their use should be at least 5 minutes.